Table 3

Baseline patient demographic and disease characteristics: pooled data from five phase III trials of SC golimumab in RA, PsA and AS

CharacteristicPlacebo±MTXGolimumab 50 mg±MTXGolimumab 100 mg±MTXTotal
Randomised patients, N6396859792303
Women, n (%)442 (69.2)413 (60.3)660 (67.4)1515 (65.8)
Race, n (%)
 Asian67 (10.5)83 (12.1)135 (13.8)285 (12.4)
 Black18 (2.8)12 (1.8)17 (1.7)47 (2.0)
 White515 (80.6)563 (82.2)781 (79.8)1859 (80.7)
 Other39 (6.1)27 (3.9)46 (4.7)112 (4.9)
Age, years
 Mean±SD49.4±13.0348.0±12.5248.4±12.5048.6±12.66
 Median (IQR)50.0 (41.0, 58.0)48.0 (40.0, 57.0)49.0 (40.0, 57.0)49.0 (40.0, 57.0)
Disease duration, years
 Mean±SD8.2±8.737.7±8.127.2±7.757.6±8.15
 Median (IQR)4.8 (1.6, 11.6)4.9 (1.4, 11.1)4.5 (1.4, 10.1)4.7 (1.4, 10.9)
CRP, mg/dL
 Mean±SD1.9±2.732.0±2.622.1±2.862.0±2.76
 Median (IQR)1.0 (0.3, 2.3)0.9 (0.3, 2.4)0.9 (0.3, 2.6)0.9 (0.3, 2.4)
HAQ-DI in RA and PsA, 0–3*, N5595428311932
 Mean±SD1.4±0.671.4±0.701.4±0.681.4±0.68
 Median (IQR)1.4 (1.0, 1.9)1.4 (0.9, 1.9)1.4 (0.9, 1.9)1.4 (0.9, 1.9)
DAS28-CRP in RA pts only, N4483986881534
 Mean±SD5.6±1.045.8±1.095.6±1.035.7±1.05
 Median (IQR)5.6 (4.8, 6.3)5.8 (5.0, 6.5)5.6 (4.9, 6.4)5.7 (4.9, 6.4)
BASDAI >4 in AS pts, n/N (%)75/78 (96.2)130/138 (94.2)135/140 (96.4)340/356 (95.5)
MTX use in RA and PsA†
 Number of MTX-treated patients156174169499
 Mean dose±SD (mg)16.0±5.0116.0±5.3016.3±5.3316.1±5.21
 Median dose (IQR) (mg)15.0 (12.5, 20.0)15.0 (12.5, 20.0)15.0 (12.5, 20.0)15.0 (12.5, 20.0)
Oral corticosteroid use in RA and PsA†
 Number of corticosteroid-treated patients270260413943
 Mean dose±SD (mg)6.6±2.596.8±2.706.8±2.606.8±2.62
 Median dose (IQR) (mg)5.0 (5.0, 10.0)6.0 (5.0, 10.0)5.0 (5.0, 10.0)5.0 (5.0, 10.0)
  • *HAQ-DI data were not collected in the GO-RAISE golimumab trial conducted in patients with AS.

  • †MTX use at baseline was not allowed in the GO-BEFORE golimumab trial in MTX-naïve patients with RA; MTX and oral corticosteroid use was very limited in patients with AS and are thus summarised only for patients with RA and PsA.

  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, 28-joint Disease Activity Score using CRP; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SC, subcutaneous.